InflaRx prices $150m share offering to fund complement pipeline
InflaRx N.V. has priced a $150 million underwritten public offering of 75 million ordinary shares at $2.00 per share, with the transaction expected to close on 7 May 2026. All shares were sold directly by the company, with proceeds earmarked for pipeline advancement, working capital, and general corporate purposes.
The offering drew participation from a wide range of institutional investors. Named participants include TCGX, described as a large healthcare-dedicated fund, alongside Farallon Capital Management, Sirenia Capital Management, Columbia Threadneedle Investments, Great Point Partners, ADAR1 Capital Management, Coastlands Capital, and Squadron Capital Management. Several large mutual funds also participated without being named individually. Guggenheim Securities acted as lead bookrunner, with Oppenheimer & Co., LifeSci Capital, Raymond James, Needham & Company, H.C. Wainwright, and Lucid Capital Markets in supporting roles.
Pipeline context
InflaRx's clinical focus centres on inhibiting C5a, a pro-inflammatory complement protein implicated in a broad range of immune-mediated diseases. Its lead candidate, izicopan, is an orally administered small molecule that blocks C5a-induced signalling via its receptor, C5aR. The company reports encouraging pharmacokinetic and pharmacodynamic data from Phase 1 and Phase 2a studies and is advancing izicopan in ANCA-associated vasculitis (AAV) and additional renal indications. The company also holds vilobelimab, an intravenously delivered anti-C5a monoclonal antibody that has demonstrated clinical activity across several studies.
The release does not specify which programmes will be prioritised for the new capital, nor does it indicate the anticipated timing of any upcoming Phase 2 or Phase 3 readouts. Investors will be watching for a more detailed capital allocation plan, particularly regarding whether izicopan's AAV programme will move into a larger registrational trial.
Market landscape
Complement-targeted therapeutics have become one of the more active corners of rare immunological disease drug development. Alexion Pharmaceuticals — now part of AstraZeneca — established the category with eculizumab and its successor ravulizumab, both of which act downstream of C5a by blocking C5 cleavage. InflaRx's approach, targeting the C5a fragment and its receptor directly, is mechanistically distinct and may offer a more targeted anti-inflammatory profile, though the clinical differentiation from approved complement therapies remains to be demonstrated in head-to-head or pivotal data.
Several other companies are pursuing C5a or C5aR inhibition, and the broader complement space has attracted significant venture and public-market capital in recent years, reflecting growing recognition of complement dysregulation across renal, haematological, and autoimmune indications. Regulatory interest has also grown: the FDA approved the C5aR antagonist avacopan (Tavneos, developed by ChemoCentryx, now part of Amgen) for AAV in 2021, establishing a precedent that may smooth InflaRx's regulatory path if izicopan generates competitive efficacy and safety data.
The $2.00 offering price implies a discount to recent trading levels that is typical for follow-on offerings of this size, and the breadth of the institutional syndicate suggests sufficient demand to clear the book at that level. For a clinical-stage company without approved revenues, securing $150 million in a single transaction is a meaningful de-risking event, extending the operating runway into a period when key clinical data should become available.